Table 3.
Treatment pattern in patients with primary and secondary GI MCL.
| Primary GI MCL | Secondary GI MCL | |||
|---|---|---|---|---|
| n | % | n | % | |
| Frontline therapy | ||||
| Observation and/or localized therapy | 6 | 28.6 | 6 | 7.6 |
| Less aggressive therapy without ASCT | 10 | 47.6 | 40 | 50.6 |
| Less aggressive therapy with ASCT | 2 | 9.5 | 17 | 21.5 |
| Aggressive therapy without ASCT | 2 | 9.5 | 5 | 6.3 |
| Aggressive therapy with ASCT | 1 | 4.8 | 11 | 13.9 |
| Missing | 1 | |||
| Single lesion | Multiple lesions in 1 organ | Multiple lesions in ≥2 organs | ||||
|---|---|---|---|---|---|---|
| n | % | n | % | n | % | |
| Frontline therapy | ||||||
| Observation and/or localized therapy | 4 | 57.1 | 1 | 16.7 | 1 | 12.5 |
| Less aggressive therapy without ASCT | 3 | 42.9 | 4 | 66.7 | 3 | 37.5 |
| Less aggressive therapy with ASCT | 0 | 0 | 1 | 16.7 | 1 | 12.5 |
| Aggressive therapy without ASCT | 0 | 0 | 0 | 0 | 2 | 25.0 |
| Aggressive therapy with ASCT | 0 | 0 | 0 | 0 | 1 | 12.5 |
| Missing | 1 | |||||
Abbreviations: GI gastrointestinal, MCL mantle cell lymphoma, ASCT autologous stem-cell transplant.